Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Cash from Operations (2020 - 2025)

Maxcyte (MXCT) has disclosed Cash from Operations for 6 consecutive years, with 7458000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 69.85% to 7458000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 39542000.0, a 110.24% decrease, with the full-year FY2024 number at 27610000.0, down 27.32% from a year prior.
  • Cash from Operations was 7458000.0 for Q3 2025 at Maxcyte, up from 9852000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 981000.0 in Q4 2023 to a low of 14411000.0 in Q1 2025.
  • A 5-year average of 5604189.47 and a median of 4834000.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 120.94% in 2022, then crashed 1200.04% in 2023.
  • Maxcyte's Cash from Operations stood at 960250.0 in 2021, then crashed by 533.83% to 6086400.0 in 2022, then skyrocketed by 116.12% to 981000.0 in 2023, then plummeted by 897.25% to 7821000.0 in 2024, then grew by 4.64% to 7458000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Cash from Operations are 7458000.0 (Q3 2025), 9852000.0 (Q2 2025), and 14411000.0 (Q1 2025).